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Emilin-1 is a protein of the elastic extracellular matrix (ECM) expressed in inter-
stitial connective tissue and in the cardiovascular system. Emilin1 null mice display 
hypotrophic remodeling of the wall of conductance arteries and increased blood pres-
sure. The protein regulates the bioavailability of TGF-β by inhibiting proteolysis of 
the proTGF-β precursor to LAP/TGF-β, a complex from which the growth factor can 
be subsequently released for receptor binding. In the absence of Emilin-1, the amount 
of active TGF-β is increased. As Emilin-1 is expressed in blood vessels starting from 
early stages of embryonic development to adulthood, a key question concerning the 
function of the protein is whether the Emilin1-/- phenotype is the result of a develop-
mental defect or the function of the protein is required for the regulation of blood 
pressure and arterial structure also in the adult. The conditional gene targeting pro-
cedure chosen to inactivate the Emilin1 gene in smooth muscle cells (SMCs) of adult 
mice included the use of ﬂ oxed Emilin1 and CreERT2 (a tamoxifen inducible Cre 
recombinase) under the control of the smooth muscle myosin heavy chain (Smmhc) 
promoter. Tamoxifen administration induced activity of Cre specifi cally in vascular 
and visceral SMCs, as revealed by X-gal staining of tissues from animals with the 
Rosa26R mutation. When Emilin1ﬂ ox/ﬂ ox mice carrying the Smmhc-CreERT2 transgene 
were given tamoxifen for 7 days, Emilin-1 disappeared completely in 10-12 days from 
start of treatment. In the same time, blood pressure increased of about 20 mmHg, a 
level that was stably maintained thereafter. 
The myogenic response of second branch meseteric arteries, evaluated using a 
pressure myograph, was found to be increased in Emilin1-/- mice. Additional experi-
ments with aorta and mesenteric artery SMC cultures from control and mutant mice 
showed that lack of Emilin-1  enhanced phosphorylation of myosin light chain 20 
when cells were stimulated with the α1-adrenergic receptor agonists phenylephrine 
or with angiotensin II. Moreover, basal cytosolic Ca2+ levels and calcium transients 
induced by stimulation with phenylephrine and angiotensin II were increased in 
SMCs from Emilin1-/- mutants. The data suggest that Emilin-1 expression is continu-
ously required for regulation of blood pressure and that the increase of TGF-β activ-
ity induced by diminished Emilin-1  stimulates, likely through alteration of intracel-
lular calcium homeostasis, contractility of vascular SMC to mechanical and chemical 
stimuli with ensuing hypertension.
